Artificial intelligence has the potential to revolutionize how drugs are discovered and change how hospitals deliver care to patients. But AI also comes with the risk of irreparable harm and perpetuating historic inequities.
Would-be health care AI regulators have been spinning in circles trying to figure out how to use AI safely. Industry bodies, investors, Congress, and federal agencies are unable to agree on which voluntary AI validation frameworks will help ensure that patients are safe. These questions have pitted lawmakers against the FDA and venture capitalists against the Coalition for Health AI (CHAI) and its Big Tech partners.
The National Academies on Tuesday zoomed out, discussing how to manage AI risk across all industries. At the event — one in a series of workshops building on the National Institute of Standards and Technology (NIST)’s AI Risk Management Framework — speakers largely rejected the notion that AI is a beast so different from other technologies that it needs totally new approaches.
This article is exclusive to STAT+ subscribers
Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect